tbuckley/cabot-search huggingface dataset:
Primary Peripheral T-Cell Lymphoma of the Colon Mimics Inflammatory Bowel Disease
Authors: Anthony Ciarallo, William Makis, Vilma Derbekyan
Journal: Clinical Nuclear Medicine (2011)

We present a case of a woman with ulcerative colitis who was referred for an F-18 FDG PET/CT after a suspicious colonoscopy and biopsy. PET/CT showed multiple elongated foci of intense FDG uptake in the colon, a pattern commonly reported with inflammatory bowel disease; however, the possibility of lymphoma was raised. Reevaluation of the biopsies with immunohistochemistry and molecular studies revealed a peripheral T-cell lymphoma and the patient was treated with a total colectomy. In this case, F-18 FDG PET/CT was very useful in determining the extent of the disease. This case also highlights a potential pitfall whereby the tubular and multifocal appearance of this lymphoma subtype can mimic the appearance of bowel involved by inflammatory bowel disease especially on novel techniques such as PET/CT enterography and PET/CT colonography.
Awards, Appointments, Agreements
Authors: K. Smigel
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article Awards, Appointments, Agreements Get access Kara Smigel Kara Smigel Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 14, 21 September 1988, Page 1094, https://doi.org/10.1093/jnci/80.14.1094 Published: 21 September 1988
Acupuncture As an Integrative Approach for the Treatment of Hot Flashes in Women With Breast Cancer: A Prospective Multicenter Randomized Controlled Trial (AcCliMaT)
Authors: Grazia Lesi, Giorgia Razzini, Muriel Assunta Musti, Elisa Stivanello, Chiara Petrucci, Benedetta Benedetti, Ermanno Rondini, Maria Bernadette Ligabue, Laura Scaltriti, Alberto Botti, Fabrizio Artioli, Pamela Mancuso, Francesco Cardini, Paolo Pandolfi
Journal: Journal of Clinical Oncology (2016)

To determine the effectiveness of acupuncture for the management of hot flashes in women with breast cancer.We conducted a pragmatic, randomized controlled trial comparing acupuncture plus enhanced self-care versus enhanced self-care alone. A total of 190 women with breast cancer were randomly assigned. Random assignment was performed with stratification for hormonal therapy; the allocation ratio was 1:1. Both groups received a booklet with information about climacteric syndrome and its management to be followed for at least 12 weeks. In addition, the acupuncture group received 10 traditional acupuncture treatment sessions involving needling of predefined acupoints. The primary outcome was hot flash score at the end of treatment (week 12), calculated as the frequency multiplied by the average severity of hot flashes. The secondary outcomes were climacteric symptoms and quality of life, measured by the Greene Climacteric and Menopause Quality of Life scales. Health outcomes were measured for up to 6 months after treatment. Expectation and satisfaction of treatment effect and safety were also evaluated. We used intention-to-treat analyses.Of the participants, 105 were randomly assigned to enhanced self-care and 85 to acupuncture plus enhanced self-care. Acupuncture plus enhanced self-care was associated with a significantly lower hot flash score than enhanced self-care at the end of treatment (P < .001) and at 3- and 6-month post-treatment follow-up visits (P = .0028 and .001, respectively). Acupuncture was also associated with fewer climacteric symptoms and higher quality of life in the vasomotor, physical, and psychosocial dimensions (P < .05).Acupuncture in association with enhanced self-care is an effective integrative intervention for managing hot flashes and improving quality of life in women with breast cancer.
P1-07-19: Analysis of HER2−Status in Breast Cancer by Mass Spectrometry in Archival, Formalin-Fixed Tissues.
Authors: M Sanders, R Sprung, A Ham, V Sanchez, S Manning, C Arteaga, D Liebler
Journal: Cancer Research (2011)

Abstract HER2 (ERBB2) is overexpressed in about 25% of breast cancers and predicts clinical benefit from trastuzumab, as well as response to anthracycline-based chemotherapy. Fluorescence in situ hybridization (FISH) to detect HER2 gene copy number and immunohistochemistry (IHC) to detect HER2 protein levels are approved by the FDA to identify HER2−positive (H2) tumors. However, the 2007 ASCO/CAP report concluded that approximately 20% of HER2 testing may be inaccurate. Further, the available data did not clearly demonstrate clear superiority of either IHC or FISH as a predictor of benefit from anti-HER2 therapy. Discordance between these methods is as high as 5%. Thus, novel complementary quantitative methods for interrogating HER2 expression in tumors are needed. Targeted protein analysis by multiple reaction monitoring mass spectrometry (MRM-MS) offers a powerful approach to configure assays for specific proteins without using antibodies. Our studies using this platform have demonstrated applicability to formalin-fixed, paraffin-embedded (FFPE) specimens. In the current studies, we used this approach to measure signals from two tryptic peptides specific to HER2, one each from the extracellular and intracellular domains, selected from among 28 candidates based on their signal intensity and sharpness of their chromatographic profiles. Preliminary studies with a HER2−overexpressing BT474 xenograft in mice demonstrated quantitation and detected previously reported HER2 ectodomain shedding. Subsequent analysis of FFPE tissue from five H2 and five triple-negative (TN) tumors yielded measurement of at least 1 femptomole of receptor for H2 tumors and less than 0.2 femptomole of receptor for TN tumors per microgram of digest analyzed. If we assume 200 picograms of protein per cell, the results suggest 110,00 to 468,000 receptors per cell in the H2 tumors and only 2,000 to 14,000 receptors per cell in the TN tumors. Despite significant biological variability in receptor levels measured among the specimens of each type, a clear separation of the H2 and TN tumors was achieved based on the peptide quantitation. This preliminary study demonstrates the potential of MRM-MS in FFPE tissue to provide an alternate approach to IHC-based protein analysis. MRM-MS offers the potential for more, accurate and robust HER2 quantification in clinical breast cancer tissues. The next phase of this work will encompass a larger sample set, including tumors with equivocal and negative FISH and/or IHC test results. Correlation with response to anti-Her2 therapy will be performed in samples with available follow-up data. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-07-19.
Awards, Appointments, Announcements
Authors: D. A. Tisevich
Journal: JNCI Journal of the National Cancer Institute (1991)

Awards, Appointments, Announcements Dorothy A. Tisevich Dorothy A. Tisevich Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 23, 4 December 1991, Pages 1716–1719, https://doi.org/10.1093/jnci/83.23.1716 Published: 04 December 1991
Spraying N-butyl-2-cyanoacrylate (Histoacryl) as a rescue therapy for gastrointestinal malignant tumor bleeding after failed conventional therapy
Authors: V. Prachayakul, P. Aswakul, U. Kachinthorn
Journal: Endoscopy (2011)

We report here on five cases of bleeding gastrointestinal malignant tumors treated by spraying N-butyl-2-cyanoacrylate (Histoacryl) on the lesion with satisfactory results ([Table 1]). The first case was a 84-year-old man who presented with recurrent upper gastrointestinal bleeding since a few days. Esophagogastroduodenoscopy (EGD) revealed a 5-cm gastric cancer at the lesser curvature with oozing. Epinephrine (1 : 20 000) was injected into the tumor to slow down the bleeding, following which Histoacryl (cyanoacrylate 0.5 mL with Lipiodol 0.8 mL per aliquot) was sprayed via a 23-G needle catheter (InterjectTM, Boston Scientific, Massachusetts, USA) ([Fig. 1]) over the tumor surface, followed by sterile water until hemostasis was achieved. The patient had no overt bleeding at 9 weeks after the procedure. The second case was a 76-year-old woman with cryptogenic cirrhosis who presented with recurrent lower gastrointestinal bleeding. Colonoscopy revealed a 5-cm sessile polyp in the ascending colon with oozing. Epinephrine was injected and Histoacryl sprayed using the same technique as described above, and the bleeding stopped. The third case was a 15-year-old boy with a metastasizing germinoma with tumor invasion of the second portion of the duodenum. The bleeding was stopped using the same technique again. The patient had recurrent bleeding 48 h later, which was successfully stopped by angio-embolization. The fourth case involved a 56-year-old man with pancreatic mass and gastric wall invasion. EGD showed a 6-cm ulcerating mass with oozing in the upper part of the lesser curvature ([Fig. 2], [3]). A metal clip was applied at the bleeding site but failed to stop it. Therefore, Histoacryl was sprayed and the bleeding stopped ([Fig. 4]). Lastly, a 62-year-old woman, a known case of advanced ampullary carcinoma invading the second portion of the duodenum, was referred for EGD after failed epinephrine injection, argon plasma coagulation (APC), and angio-embolization. Histoacryl spray was again used to stop the bleeding.
Abstract 304: Proinflammatory secretory chemokine CXCL8 regulates intercellular cross-talk in the breast cancer tumor microenvironment
Authors: Casey Jussim, Andrea L. George, Shilpi Rajoria, Robert Suriano, Arulkumaran Shanmugam, Abraham Mittelman, Raj K. Tiwari
Journal: Cancer Research (2012)

Abstract The cellular composition of the tumor microenvironment (TME) and soluble effector molecules mediating intercellular cross-talk are important therapeutic and preventive targets for breast cancer. Chemokines released within the TME work in a synergistic and reciprocal manner to induce malignant progression of tumor cells. CXCL8, a proinflammatory CXC chemokine shown to be released within the TME, can act as a chemoattractant, angiogenic factor, and inflammatory factor via cellular receptors CXCR1 and CXCR2. However, the specific role of CXCL8 in the signaling cascades within the tumor microenvironment has yet to be fully classified and warrants further investigation. Treatment of human breast cancer cell lines MCF-7, MDA-MB-231, and T47D with 50nM exogenous CXCL8 enhanced the expression of CXCR2. The acquisition of chemokine receptors by tumor cells, in this case CXCR2, can mediate phenotypic changes that enhance migratory and invasive potential. Treatment of these human breast cancer cell lines with 50nM exogenous CXCL8 resulted in phenotypic morphology changes characteristic of an epithelial-to-mesenchymal transition (EMT), a phenomenon commonly exhibited by metastatic tumor cells. We validated this phenomenon with 50nM exogenous CXCL8 treatment, which led to enhanced expression of both Slug (Snail2) and Twist in all three human breast cancer cell lines. Furthermore, we observed that treatment with 50nM exogenous CXCL8 promoted the migration and invasion of these breast cancer cell lines in an in vitro modified Boyden chamber assay. These results suggest that CXCL2 secreted from cells within the TME act to induce characteristic changes in human breast cancer cells, propagating the transition to more aggressive tumors. Tumor-associated macrophages (TAMs) are an important component of the heterogeneous population of cells that make up the TME. Breast cancer cells exposed to conditioned media from human monocytic cell lines THP-1 and U937, previously differentiated with 12-O-tetradecanoylphorbol-13-acetate (TPA), exhibited distinct morphology changes characteristic of EMT and enhanced migratory and invasive ability, similar to exogenous CXCL8 treatment. Together, our results suggest that CXCL8 can have profound implications in determining the fate of tumor cells by engaging in extensive cross-talk within the TME, thus providing a potential target for the treatment and prevention of breast cancer tumor progression and metastasis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 304. doi:1538-7445.AM2012-304
Abstract 1172: The impact of siRNA targeting Colon Cancer Associated Transcript 1 (CCAT-1) on proliferation of HT-29 cells
Authors: Victoria Tsivin, David Halle, Ali O. Gure, Vera Pavlov, Marina Roistacher, Nadia Ilyiayev, Stella Mitrani-Rosenbaum, Alexander Stojadinovic, Barry Trink, Abraham Rubinstein, Aviram Nissan
Journal: Cancer Research (2011)

Abstract Introduction: Colon cancer Associated Transcript-1 (CCAT-1) is a non-coding RNA transcript highly expressed in colorectal cancer (CRC) but not in normal colonic tissue. The role of CCAT-1 in tumorigenesis is yet to be defined. Small interfering RNAs (siRNA) are a group of sequence-specific posttranscriptional gene silencing molecules. Recent advances in the design and delivery of targeting siRNA molecules allows efficient and highly specific gene silencing in mammalian systems. The most common application of siRNA gene-silencing in oncology is to identify loss-of-function phenotypes in genes that will result in decreased proliferation or death of cancer cells. Aim: To study the role of colon cancer associated transcript 1 (CCAT-1) in proliferation of human colon cancer cells using RNA interference. Methods: Small interfering RNAs (siRNA) targeting CCAT-1 were transfected into HT-29 colon cancer cells. At day one, 80×105 HT-29 cells per well were plated and suspended in RPMi 1640 medium. At day two, 50 pmol CCAT-1 siRNA and 0.5 µl lipofectamine 2000 were added to each well. CCAT-1 expression was studied by real-time PCR in order to evaluate gene silencing. Cell proliferation was studied by MTT incorporation assay. Twenty four hrs after transfection, 50 µl of MTT were added to the cells media and incubated for 4 h at 37° C. The purple Formazan product, converted MTT, was dissolved by the addition of 150µl/well DMSO and OD readings were obtained at 550 nm. Results:By examining AV average OD readings at 550 nm, untreated HT-29 cells (10 wells), cells treated with lipofectamine 2000 (10 wells) and cells silenced by siRNA of CCAT-1 (10 wells) showed a significant decrease in proliferation: 2.4±0.64, 1.54±0.63, 0.8±0.14 respectively (p=0.002). Furthermore, comparing AV OD readings between 24 and 48 h in the silenced cells, showed a decrease of 38% in proliferation. This was compared to untransfected cells and cells treated with lipofectamine 2000 which showed an increase of 39% and 22% respectively. Twenty four hrs after transfection, real time PCR results showed a reduction in CCAT-1 RNA levels of 70% compared to controls and 48 hrs after transfection, CCAT-1 RNA levels were reduced to 55% of baseline. Conclusions: Our results may support a role for CCAT-1 in the regulation of colon cancer cell proliferation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1172. doi:10.1158/1538-7445.AM2011-1172
Severe Hypoglycemia Secondary to a Nonpancreatic Fibrosarcoma with Insulin Activity
Authors: J. Thomas August, Howard H. Hiatt
Journal: New England Journal of Medicine (1958)

THE syndrome of hypoglycemia secondary to a nonpancreatic tumor has been reported on several occasions.1 2 3 4 5 6 7 8 9 10 11 12 13 14 We recently studied a patient with frequent and protracted episodes of hypoglycemia that ceased when a large intrathoracic fibrosarcoma was removed. Our data suggest that the disturbance in carbohydrate metabolism was the result of secretion by the intrathoracic neoplasm of an agent with insulin activity.Case ReportM. V. (B.I.H. 82200), an 82-year-old Jewish widow, entered the Beth Israel Hospital on December 24, 1956, for the 4th time. She had been active and well until 2 months previously, when she began to experience episodes of . . .
Asbestos — Still a Carcinogen
Authors: Philip J. Landrigan
Journal: New England Journal of Medicine (1998)

Asbestos is an important cause of human illness. Clinical and epidemiologic studies have established incontrovertibly that asbestos causes cancer of the lung, malignant mesothelioma of the pleura and peritoneum, cancer of the larynx, and certain gastrointestinal cancers.1 Asbestos also causes asbestosis, a progressive fibrotic disease of the lungs. The risk of these diseases increases with cumulative exposure and also with the length of time since the first exposure. Asbestos has been declared a proven human carcinogen by the Environmental Protection Agency (EPA) and by the International Agency for Research on Cancer of the World Health Organization.2,3 The total number . . .
Abstract 5096: Identification of biomarkers and therapeutic targets in oral squamous cell carcinomas through comparative proteomic analyses
Authors: Kee-Koon Tan, Yeou-Guang Tsay, Jeng-Fan Lo
Journal: Cancer Research (2011)

Abstract Background: Oral squamous carcinoma cell (OSCC) is the sixth most common worldwide cancer and responsible for about 640,000 new cases each year worldwide. Recently, a small subpopulation of oral cancer tumor cells with self-renewal capacity, or oral cancer-tumor initiating cells (OC-TICs), have been characterized in our lab. Accumulating evidence suggests that these OC-TICs contribute to tumor initiation, maintenance and metastasis while they are resistant to radiotherapy and chemotherapy. Thus, identification of the biomarkers and therapeutic targets for these cells should help the development of new diagnostics and therapeutics for oral cancers. Methods: Sphere formation assay was used to enrich the OC-TIC population, whose proteins were resolved in a SDS polyacrylamide gel along with those from parental cells. The proteins within the gels were subjected to tryptic digestion and subsequent 18O peptide labeling. Liquid chromatography-mass spectrometry was programed to collect the tandem mass spectra (MS/MS) of peptides from proteins with &amp;gt;2-fold increase in OC-TICs. These MS/MS were matched against the NCBI protein database with TurboSequest search engine and the results were interpreted by bioinformatics tools. Results: With such a new platform, we found that 61 proteins were up-regulated in OC-TICs proteomes. In order to define collective functional roles of the identified proteins, these proteins were categorized based on the information in Gene Ontology database. Molecular function analyses showed that, besides binding, catalytic activity and transporter activity, a majority of proteins appear to participate in protein metabolism and modification, protein/vesicle trafficking and carbohydrate metabolism. Meanwhile, cellular compartment studies revealed that most proteins appear to be from plasma membrane and mitochondria. Conclusion: Our results indicate that OC-TICs behave differently in protein metabolism/trafficking and carbohydrate metabolism. This data set will be used to identify novel biomarkers or therapeutic targets for oral cancer-tumor initiating cells (OC-TICs). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5096. doi:10.1158/1538-7445.AM2011-5096
Abstract 2101: Differential mtDNA sequence variants in primary tissues of colorectal adeno-polyps
Authors: Gregory Adams, Sharifeh Mehrabi, Yupha Vatcharapijarn, Joyce A. Akwe, Xuebiao Yao, Felix O. Aikhionbare
Journal: Cancer Research (2012)

Abstract Introduction: Increasing evidence suggest that mitochondrial alterations involved in cellular signal pathways have been associated with tumorigenesis. Differentially diagnosing progressive stages of colorectal adenomatous polyps is important for therapeutic intervention and surveillance. We hypothesized that Mitochondrial DNA (mtDNA) variants in colorectal adenomatous polyps are stage-specific genetic changes. We aimed to identify the genetic mtDNA mutations present in the early stages of colorectal cancer. Methods: MtDNA sequence variants among the different types of colorectal adenomatous polyps: Tubular, Tubulovillous and Villous adenomatous were analyzed from sixty-four tissue samples (33 tumor 31 matched surrounding normal tissue (NST)) with patients mean age 57.1±7. Two mtDNA regions were screened from each sample with two primer pairs spanning 8282-to-10107 and 11673-to-13950bp comprised of the MT-NC7, MT-TK, MT-ND3, ATPase 6, ATPase 8, COX III, ND3, ND4L, ND4 and ND5 genes. The presence of polymorphisms and other sequence variants of mtDNA were also evaluated using the high-resolution restriction endonucleases and PCR based sequencing. Results: Forty-two variants were observed of which 18 of 42 (42%) were not previously reported in the MITODAT reference database. The distribution of observed mutations included, 31% (13/42) Tubular, 52% (22/42) Tubulovillous, 45% (19/42) Villous, 45% (19/42) colorectal cancer (including FAP and JVP). Notably, unreported germline variant, G8573A, in the ATPase 8 gene region was found in 100% tubulovillous adenomas, but not any other samples. A heteroplasmic variant A11873G, in the MTND4 gene was detected in 67% tubular, 78% tubulovillous, 71% villous and 38% cancer subtypes. Given that mutations in ATPase 8 genes inhibits the production of ATP from ADP, and mutations in MTND4 genes prevent the normal interactions of complex I with ubiquinone, affecting the generation of ATP, these observed variants may influence the early stages of colorectal tumor. Conclusion: Therefore, our findings suggest that certain mtDNA sequence variants may contribute as a framework for further differentiation studies of stages of colorectal adeno-polyps. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2101. doi:1538-7445.AM2012-2101
A Controlled Trial of Fluconazole or Amphotericin B to Prevent Relapse of Cryptococcal Meningitis in Patients with the Acquired Immunodeficiency Syndrome
Authors: W G Powderly, M S Saag, G A Cloud, P Robinson, R D Meyer, J M Jacobson, J R Graybill, A M Sugar, V J McAuliffe, S E Follansbee
Journal: New England Journal of Medicine (1992)

After primary treatment for cryptococcal meningitis, patients with the acquired immunodeficiency syndrome (AIDS) require some form of continued suppressive therapy to prevent relapse.
Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA
Authors: R. Houot, C. Soussain, H. Tilly, C. Haioun, C. Thieblemont, O. Casasnovas, K. Bouabdallah, F. Morschhauser, S. Le Gouill, G.A. Salles, K. Hoang-Xuan, S. Choquet, T. Marchand, C. Laurent, C. Pangault, T. Lamy
Journal: Annals of Oncology (2016)